Letters
Journal of Medicinal Chemistry, 2006, Vol. 49, No. 23 6637
(15) Bolger, M. B.; Jorgensen, E. C. Molecular interactions between
thyroid hormone analogs and the rat liver nuclear receptor. Partition-
ing of equilibrium binding free energy changes into substituent group
interactions. J. Biol. Chem. 1980, 255, 10271-10278.
(16) Dietrich, S. W.; Bolger, M. B.; Kollman, P. A.; Jorgensen, E. C.
Thyroxine analogues. 23. Quantitative structure-activity correlation
studies of in vivo and in vitro thyromimetic activities. J. Med. Chem.
1977, 20, 863-880.
(17) Koerner, D.; Schwartz, H. L.; Surks, M. L.; Oppenheimer, J. H.
Binding of selected iodothyronine analogues to receptor sites of
isolated rat hepatic nuclei. High correlation between structural
requirements for nuclear binding and biological activity. J. Biol.
Chem. 1975, 250, 6417-6423.
(18) Baxter, J. D.; Goede, P.; Apriletti, J. W.; West, B. L.; Feng, W.;
Mellstro¨m, K.; Fletterick, R. J.; Wagner, R. L.; Kushner, P. J.;
Ribeiro, R. C. J.; Webb, P.; Scanlan, T. S.; Nilsson, S. Structure-
based design and synthesis of a thyroid hormone receptor (TR)
antagonist. Endocrinology 2002, 143, 517-524.
References
(1) Lazar, M. A. Thyroid hormone receptors: multiple forms, multiple
possibilities. Endocr. ReV. 1993, 14, 184-193.
(2) Wagner, R. L.; Apriletti, J. W.; McGrath, M. E.; West, B. L.; Baxter,
J. D.; Fletterick, R. J. A structural role for hormone in the thyroid
hormone receptor. Nature 1995, 378, 690-697.
(3) Darimont, B. D.; Wagner, R. L.; Apriletti, J. W.; Stallcup, M. R.;
Kushner, P. J.; Baxter, J. D.; Fletterick, R. J.; Yamamoto, K. R.
Structure and specificity of nuclear receptor-coactivator interactions.
Genes DeV. 1998, 12, 3343-3356.
(4) Wagner, R. L.; Huber, R. B.; Shiau, A. K.; Kelly, A.; Cunha Lima,
S. T.; Scanlan, T. S.; Apriletti, J. W.; Baxter, J. D.; West, B. L.;
Fletterick, R. J. Hormone selectivity in thyroid hormone receptors.
Mol. Endocrinol. 2001, 15, 398-410.
(5) Dow, R. L.; Schnelier, S. R.; Paight, E. S.; Hank, R. F.; Chiang, P.;
Cornelius, P.; Lee, E.; Newsome, W. P.; Swick, A. G.; Spitzer, J.;
Hargrove, D. M.; Patterson, T. A.; Pandit, J.; Chrunyk, B. A.;
LeMotte, P. K.; Danley, D. E.; Rosner, M. H.; Ammirati, M. J.;
Simons, S. P.; Schulte, G. K.; Tate, B. F.; DaSilva-Jardine, P.
Discovery of a novel series of 6-azauracil-based thyroid hormone
receptor ligands: potent, TR beta subtype-selective thyromimetics.
Bioorg. Med. Chem. Lett. 2003, 13, 379-382.
(19) Chiellini, G.; Nguyen, N. H.; Apriletti, J. W.; Baxter, J. D.; Scanlan,
T. S. Synthesis and biological activity of novel thyroid hormone
analogues: 5′-aryl substituted GC-1 derivatives. Bioorg. Med. Chem.
Lett. 2002, 10, 333-346.
(6) Ye, L.; Li, Y. L.; Mellstro¨m, K.; Mellin, C.; Bladh, L. G.; Koehler,
K. F.; Garg, N.; Garcia Collazo, A. M.; Litten, C.; Husman, B.;
Persson, K.; Ljunggren, J.; Grover, G.; Sleph, P. G.; George, R.;
Malm, J. Thyroid receptor ligands. 1. Agonist ligands selective for
the thyroid receptor beta1. J. Med. Chem. 2003, 46, 1580-1588.
(7) Hangeland, J. J.; Doweyko, A. M.; Dejneka, T.; Friends, T. J.;
Devasthale, P.; Mellstrom, K.; Sandberg, J.; Grynfarb, M.; Sack, J.
S.; Einspahr, H.; Fa¨rnegardh, M.; Husman, B.; Ljunggren, J.; Koehler,
K.; Sheppard, C.; Malm, J.; Ryono, D. E. Thyroid receptor ligands.
Part 2: Thyromimetics with improved selectivity for the thyroid
hormone receptor beta. Bioorg. Med. Chem. Lett. 2004, 14, 3549-
3553.
(20) Nguyen, N. H.; Apriletti, J. W.; Lima, S. T. C.; Webb, P.; Baxter, J.
D.; Scanlan, T. S. Rational design and synthesis of a novel thyroid
hormone antagonist that blocks coactivator recruitment. J. Med.
Chem. 2002, 45, 3310-3320.
(21) Lim, W.; Nguyen, N. H.; Yang, H. Y.; Scanlan, T. S.; Furlow, J. D.
A thyroid hormone antagonist that inhibits thyroid hormone action
in vivo. J. Biol. Chem. 2002, 277, 35664-35670.
(22) Bates, W. B.; Gabel, C. J.; Ji, J.; Rama-Devi, T. Synthesis of phenolic
natural products using palladium catalyzed coupling reactions.
Tetrahedron 1995, 51, 8199-8212.
(23) Since there are no available crystallographic structures of antagonists
bound to TR, a partial homology model of the LBD of TRâ in the
antagonist conformation was constructed using the crystallographic
structure of hTRâ/3-[3,5-dibromo-4-(3-isopropyl-4-methoxyphen-
oxy)phenyl]propionate (7), (in which H12 adopts the canonical
agonist conformation; PDB accession code 2j4a) and hRAR-R/BMS-
614 (where H12 in an antagonist orientation; PDB accession code
1DKF). The experimental procedure can be found in the Supporting
Information.
(24) Yokoyama, N.; Walker, G. N.; Main, A. J.; Stanton, J. L.; Morrissey,
M. M.; Boehm, C.; Engle, A.; Neubert, A. D.; Wasvary, J. M.;
Stephan, Z. F.; Steele, R. E. Synthesis and structure-activity
relationships of oxamic acid and acetic acid derivatives related to
L-thyronine. J. Med. Chem. 1995, 38, 695-707.
(25) DeLano, W. L. The PyMOL Molecular Graphics System; DeLano
(26) Carlsson, B.; Singh, B. N.; Temciuc, M.; Nilsson, S.; Li, Y. L.;
Mellin, C.; Malm, J. Synthesis and preliminary characterization of a
novel antiarrhythmic compound (KB130015) with an improved
toxicity profile compared with amiodarone. J. Med. Chem. 2002, 45,
623-630.
(27) Grover, J. G.; Mellstro¨m, K.; Ye, L.; Malm, J.; Li, Y.-L.; Bladh,
L.-G.; Sleph, P. G.; Smith, M. A.; George, R.; Vennstro¨m, B.;
Mookhtiar, K.; Horvath, R.; Speelman, J.; Egan, D.; Baxter, J. D.
Selective thyroid hormone receptor-â activation: a strategy for
reduction of weight, cholesterol, and Lp(a) with reduced cardiovas-
cular liability. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 10067-10072.
(8) Sandler, B.; Webb, P.; Apriletti, J. W.; Huber, R. R.; Togashi, M.;
Cunha Lima, S. T.; Juric, S.; Nilsson, S.; Wagner, R.; Fletterick, R.
J.; Baxter, J. D. Thyroxine-thyroid hormone receptor interactions.
J. Biol. Chem. 2004, 279, 55801-55808.
(9) Borngraeber, S.; Budny, M. J.; Chiellini, G.; Cunha-Lima, S. T.;
Togashi, M.; Webb, P.; Baxter, J. D.; Scanlan, T. S.; Fletterick, R.
J. Ligand selectivity by seeking hydrophobicity in thyroid hormone
receptor. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 15358-15363.
(10) The distinction between “direct”, “indirect”, and “passive” antagonists
has been outlined in the following. Hedfors, A° .; Appelqvist, T.;
Carlsson, B.; Bladh, L.-B.; Litten, C.; Agback, P.; Grynfarb, M.;
Koehler, K. F.; Malm, J. Thyroid receptor ligands. 3. Design and
synthesis of 3,5-dihalo-4-alkoxyphenylalkanoic acids as indirect
antagonists of the thyroid hormone receptor. J. Med. Chem. 2005,
48, 3114-3117.
(11) Reid, D. G.; Maclachlan, L. K.; Voyle, M.; Leeson, P. D. A proton
and fluorine-19 nuclear magnetic resonance and fluorescence study
of the binding of some natural and synthetic thyromimetics to
prealbumin (transthyretin). J. Biol. Chem. 1989, 264, 2013-2023.
(12) Shulkin, B. L.; Bolger, M. B.; Utiger, R. D. Thyroid hormone analog
inhibition of hepatic 5′-iodothyronine deiodinase activity. J. Endo-
crinol. InVest. 1988, 11, 657-661.
(13) Koehrle, J.; Auf’mkolk, M.; Rokos, H.; Hesch, R. D.; Cody, V. Rat
liver iodothyronine monodeiodinase. Evaluation of the iodothyronine
ligand-binding site. J. Biol. Chem. 1986, 261, 11613-11622.
(14) Tropsha, A. E.; Rakhmaninova, A. B.; Iaguzhinskii, L. S. Configration
and properties of a binding site for thyroid hormones on a specific
receptor. Bioorg. Khim. 1984, 10, 483-492.
JM060521I